Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This registry will assess clinical outcomes following the use of Cryopreserved Amniotic Membrane (CAM) for the treatment of orthopedic and various other conditions. This registry will collect outcomes data via a registry of up to 100 patients who have received treatment with CAM in the post-market setting. Patients will be enrolled from up to five healthcare centers.
The objective of this registry is to collect outcomes data via a registry on the uses of CAM in the post-market setting, including:
An additional objective is to determine standard of care follow-up for the target treatments, including effectiveness metrics used and typical follow-up schedule.
This registry is intended to collect clinical data from patients for analysis purposes only and will not be used to treat patients. The plan does not allow for any deviation from standard of care practice. Therefore, there is no added risk to patients from participating in the registry.
The sponsor will use an electronic data capture (EDC) system for capturing all the data from the sites. The system will be built and validated prior to initiation of the sites. Each participating physician or appropriately trained designee shall enter data into the EDC system, providing all applicable data and documentation to the sponsor. Data will be reviewed for missing data, data consistency, and reasonableness of responses. Discrepancies will be resolved through a formal query process within the EDC system, and may involve direct contact with hospital staff.
The conduct of the registry will be supervised through a process of centralized and on-site monitoring. The sponsor may remotely monitor the registry for data completeness and for adverse events. On-site monitoring will be implemented as necessary throughout the course of the registry. The physician/clinic will provide direct access to source data/documents for registry-related monitoring, audits and IRB review.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CAM | Biological | Cryopreserved Amniotic Membrane |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of related serious adverse events | Number of related serious adverse events occurred | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Visual Analog Scale | Change in pain score (0-10; higher scores mean worse outcome) | 12 weeks |
| Change in analgesic use | Change in analgesic use |
Not provided
Inclusion Criteria:
• A patient is suitable for inclusion in this registry if the patient has been treated with CAM for any indication as per the standard of care practice.
Exclusion Criteria:
• Patients are excluded from registry enrollment if they are under the age of 22 years.
Not provided
Not provided
Not provided
A patient is suitable for inclusion in this registry if the patient has been treated with CAM for any indication as per the standard of care practice.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Theodore Heise, PhD | MED Institute Inc. | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Regenerative Medicine and Pain Management Physicians | Gulf Breeze | Florida | 32563 | United States | ||
| Foot and Ankle Specialists of South Jersey |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009140 | Musculoskeletal Diseases |
| D014947 | Wounds and Injuries |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 12 weeks |
| Change in wound size | Change in wound size | 12 weeks |
| Time to complete wound closure | Time to complete wound closure | 12 weeks |
| Voorhees Township |
| New Jersey |
| 08043 |
| United States |